Literature DB >> 11192331

Thyroid-associated ophthalmopathy: clinical features, pathogenesis, and management.

M Yamada1, A W Li, J R Wall.   

Abstract

Thyroid-associated ophthalmopathy (TAO) is a progressive eye disorder characterized by immune-mediated inflammation of the extraocular muscles and orbital connective tissue. TAO is linked, in a unique way, with thyroid autoimmunity, in particular Graves' hyperthyroidism. Our working hypothesis for the pathogenesis of TAO is that recognition of a thyrotropin receptor (TSHR)-like protein in the orbital preadipocytes by antibodies may be the initial event leading to homing of lymphocytes into the orbital tissues. In the course of thyroid inflammation, antibodies and T cells reactive against G2s expressed in thyroid membranes cross-react with the protein in the eye muscle fiber, leading to eye muscle damage and dysfunction. Those patients with anti-G2s antibodies develop ocular myopathy. Antibodies against flavoprotein, the 64-kDa protein, which are produced in the context of eye muscle fiber damage and mitochondrial rupture, are sensitive markers of immune-mediated fiber necrosis in patients with ophthalmopathy but do not directly damage the eye muscle. Antibodies against type XIII collagen, which is localized in the plasma membranes of orbital fibroblast, may be a new marker for the congestive ophthalmopathy subtype of TAO. The measurement of antibodies against key eye muscle and orbital connective tissue autoantigens may have a role in the management of active ophthalmopathy and its prediction in patients with Graves' hyperthyroidism.

Entities:  

Mesh:

Year:  2000        PMID: 11192331     DOI: 10.1080/10408360091174303

Source DB:  PubMed          Journal:  Crit Rev Clin Lab Sci        ISSN: 1040-8363            Impact factor:   6.250


  13 in total

Review 1.  Pharmacological treatments for thyroid eye disease.

Authors:  Sara P Modjtahedi; Bobeck S Modjtahedi; Ahmad M Mansury; Dinesh Selva; Raymond S Douglas; Robert A Goldberg; Igal Leibovitch
Journal:  Drugs       Date:  2006       Impact factor: 9.546

2.  Antibodies targeting the calcium binding skeletal muscle protein calsequestrin are specific markers of ophthalmopathy and sensitive indicators of ocular myopathy in patients with Graves' disease.

Authors:  B Gopinath; R Musselman; N Beard; S El-Kaissi; J Tani; C-L Adams; J R Wall
Journal:  Clin Exp Immunol       Date:  2006-07       Impact factor: 4.330

Review 3.  Extracellular matrix molecules: potential targets in pharmacotherapy.

Authors:  Hannu Järveläinen; Annele Sainio; Markku Koulu; Thomas N Wight; Risto Penttinen
Journal:  Pharmacol Rev       Date:  2009-06       Impact factor: 25.468

4.  Pathogenesis of thyroid-associated ophthalmopathy: does autoimmunity against calsequestrin and collagen XIII play a role?

Authors:  Hooshang Lahooti; Kishan R Parmar; Jack R Wall
Journal:  Clin Ophthalmol       Date:  2010-05-14

5.  Presence of thyroid-associated ophthalmopathy in Hashimoto's thyroiditis.

Authors:  Emrah Kan; Elif Kilic Kan; Gülcin Ecemis; Ramis Colak
Journal:  Int J Ophthalmol       Date:  2014-08-18       Impact factor: 1.779

6.  Effect of near-total thyroidectomy on thyroid orbitopathy due to toxic goiter.

Authors:  Yasser A Elsayed; Atif M Abdul-Latif; Mukhtar F Abu-Alhuda; Hosam A-F Halim
Journal:  World J Surg       Date:  2009-04       Impact factor: 3.352

Review 7.  Eye muscle antibodies in Graves' ophthalmopathy: pathogenic or secondary epiphenomenon?

Authors:  T Mizokami; M Salvi; J R Wall
Journal:  J Endocrinol Invest       Date:  2004-03       Impact factor: 4.256

8.  Update on thyroid eye disease and management.

Authors:  Erick D Bothun; Ryan A Scheurer; Andrew R Harrison; Michael S Lee
Journal:  Clin Ophthalmol       Date:  2009-10-19

Review 9.  Beyond dry eye: how co-morbidities influence disease phenotype in dry eye disease.

Authors:  Yonghoon Lee; Minji Kim; Anat Galor
Journal:  Clin Exp Optom       Date:  2021-08-08       Impact factor: 2.742

10.  Novel single-nucleotide polymorphisms in the calsequestrin-1 gene are associated with Graves' ophthalmopathy and Hashimoto's thyroiditis.

Authors:  Hooshang Lahooti; Daniele Cultrone; Senarath Edirimanne; John P Walsh; Leigh Delbridge; Patrick Cregan; Bernard Champion; Jack R Wall
Journal:  Clin Ophthalmol       Date:  2015-09-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.